Skip to Main Content
Beta test
our new site.
(
NLM Technical Bulletin
)
Home
Search
Study Topics
Glossary
Full Text View
Tabular View
No Study Results Posted
Related Studies
Safety and Efficacy Study of Botulinum Toxin Type A for the Treatment of Neurogenic Overactive Bladder
This study has been terminated.
( In agreement with FDA the study was terminated based on data available. )
Study NCT00439140 Information provided by Allergan
First Received on February 21, 2007. Last Updated on April 8, 2013
History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Overactive Bladder
Additional conditions recognized in this trial
Urinary Bladder, Overactive
More general conditions related to this trial
Signs and Symptoms
Urinary Bladder Diseases
Urologic Diseases
Urological Manifestations
Interventions listed in this trial
botulinum toxin Type A 200U
botulinum toxin Type A 300U
Normal Saline (Placebo)
Additional drug interventions recognized in this trial
Botulinum Toxins
Botulinum Toxins, Type A
Trichostatin A
More general drug interventions related to this trial
Anti-Dyskinesia Agents
Anti-Infective Agents
Antifungal Agents
Central Nervous System Agents
Enzyme Inhibitors
Histone Deacetylase Inhibitors
Molecular Mechanisms of Pharmacological Action
Neuromuscular Agents
Peripheral Nervous System Agents
Pharmacologic Actions
Physiological Effects of Drugs
Protein Synthesis Inhibitors
Therapeutic Uses
Sponsors listed in this trial
Allergan
Back to top of Main Content
